Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exemestane with or without MM-121 in postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer
2010-020395-28Phase 2Completed
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Feb 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing MM-121 + exemestane with Exemestane monotherapy (2 arms). Primary endpoint: Progression-free survival. Started Feb 2011; status: completed.
02
Drugs
seribantumabexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-020395-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020395-28.